Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.

ABSTRACT:

Objectives

Tenofovir alafenamide produces lower plasma tenofovir and higher intracellular tenofovir diphosphate (DP) concentrations than tenofovir disoproxil fumarate but it is likely a victim of interactions with rifampicin. We aimed to investigate the pharmacokinetics of tenofovir alafenamide/emtricitabine with rifampicin.

Patients and methods

Healthy volunteers received tenofovir alafenamide/emtricitabine at 25/200 mg once daily, followed by tenofovir alafenamide/emtricitabine + rifampicin daily followed by tenofovir disoproxil fumarate. Plasma tenofovir alafenamide, tenofovir, emtricitabine and intracellular tenofovir-DP and emtricitabine triphosphate pharmacokinetics and genetic polymorphisms were assessed.

Results

Tenofovir alafenamide exposure decreased when te

SUBMITTER: Cerrone M 

PROVIDER: S-EPMC8204702 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature